bextra attorney

Subject = bextra attorney
Description = find an attorney for bexrta
Category = personal injury

lawsuit The FDA removal comes after a large US managed health care organization, Kaiser Permanente, banned the dispensing of Bextra until further research is conducted on the cardiovascular side effects of the drug. A lawsuit letter to healthcare providers was sent by Pfizer on October 15, 2004 explaining Bextra’s associated risks of heart attack, stroke and skin disease.

Bextra, Vioxx and Celebrex are all members of the lawsuit COX-2 Inhibitor group of arthritis pain medications. With the removal of Bextra and Vioxx from the market, Celebrex remains the only Cox-2 inhibitor available. Studies have also linked Celebrex to cardiovascular side effects lawsuit and the fFDA has required that Pfizer put a black box warning on the Celebrex warning label. Bextra (generic name: valdecoxib) , a Cox-2 Inhibitor drug, is in the same drug family as lawsuit Vioxx, Celebrex and Naproxen. People prescribed Bextra have experienced a higher number of heart attacks, strokes and other cardiovascular problems. Bextra is a COX-2 inhibitor, marketed by Pharmacia Corporation and Pfizer Inc. in lawsuit the United States. The drug is prescribed for the treatment of osteoarthritis, adult rheumatoid arthritis, and the pain associated with menstrual cramping.

FDA advisory committee hearings held in February 2005 examined whether lawsuit Celebrex and Bextra offered enough benefits to stay on the market, if they needed stronger warnings and what further research was needed. The advisers met from February 16, 2005 through February 18, 2005 lawsuit and ultimately voted to keep Bextra on the market. The New York Times reported that 10 of the 32 government drug advisers who voted to keep Bextra and the other COX-2 drugs on lawsuit the market have consulted for pharmaceutical manufacturers. If these 10 advisers had not cast their votes, the committee would have voted 12 to 8 that Bextra should be withdrawn. Bextra (generic name: valdecoxib) lawsuit , a Cox-2 Inhibitor drug,